Please login to the form below

Not currently logged in
Email:
Password:

EM Imaging appoints new chairman

John Jeans to bring firm to forefront of molecular imaging market
EM Imaging John Jeans

The Board of Edinburgh Molecular Imaging (EM Imaging) has appointed John Jeans as non-executive chairman.

Jeans joins with over 35 years of experience having formerly held leadership positions at Bristol-Myers Squibb, Johnson & Johnson and Amersham.

In 2014, Jeans was appointed by the prime minister as the UK's government life science champion for medical technology and two years prior was awarded CBE for services to healthcare and science.

He said: “The team at Edinburgh Molecular Imaging have made great progress in establishing a strong portfolio of optical imaging opportunities and it's a privilege to be joining the company as it enters this exciting period of further development.”

Ian Wilson, CEO of EM Imaging, said: “With his extensive experience in the healthcare and diagnostics sector John is an extremely valuable addition to the company.

“His deep expertise and leadership skills will be central to supporting EM Imaging in bringing its novel optical imaging technology to the forefront of the global molecular imaging market.”

Jeans also chairs the board of UK Biocentre, and has sat on advisory panels for the MRC, EPSRC, NIHR and the Wellcome Trust. 

7th September 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics